HCC Prevalence and Histopathological Findings in Liver Explants of Patients With Hereditary Tyrosinemia Type 1

Imagem de Miniatura
Arquivos
art_NETO_HCC_Prevalence_and_Histopathological_Findings_in_Liver_Explants_2014.PDF (1019.62 KB)
Citações na Scopus
32
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
NETO, Joao Seda
PORTA, Adriana
FONSECA, Eduardo A.
FEIER, Flavia H.
PUGLIESE, Renata
MIURA, Irene K.
CHAPCHAP, Paulo
PORTA, Gilda
Citação
PEDIATRIC BLOOD & CANCER, v.61, n.9, p.1584-1589, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. Untreated tyrosinemia type 1 (HT1) is manifested by liver failure associated with renal tubular dysfunction, growth failure, and rickets. The indication for liver transplantation (LT) is restricted to non-responders to 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione (NTBC) treatment, patients not treated with NTBC or for patients with HCC. The aim of this study is to report on a series of NTBC naive HT1 patients submitted to LT along with the prevalence of HCC in their liver explants. Procedure. This is a retrospective study of 16 children with HT1 who underwent liver transplantation between January 1993 and December 2012. Results. Clinical features: liver failure in 12 (75%), growth failure in 4 (25%), rickets in 5 (31.2%), hypertrophic cardiomyopathy in three (18.7%), and renal tubulopathy in seven patients (43.7%). Median AFP level was 64,335 ng/ml. Abdominal CT scans showed multiple nodules in most patients. Histopathology of the explants showed cirrhosis in all patients and HCC in 12 (75%), 3 with microvascular invasion. The majority of the tumors were well differentiated. Patient survival rate was 86% at a median follow-up of 6.6 years. All survivors were tumor-free with no adjuvant chemotherapy. Conclusion. In countries where neonatal screening programs are not effective and NTBC treatment is not widely available, LT still plays an important role in the treatment of children with HT1. An early indication in patients who present with multinodular livers can also serve to treat an otherwise underdiagnosed HCC condition. (c) 2014 Wiley Periodicals, Inc.
Palavras-chave
children, hepatocellular carcinoma, liver transplantation, outcomes, tyrosinemia
URI
https://observatorio.fm.usp.br/handle/OPI/8277
Referências
  1. Arikan C, 2006, PEDIATR TRANSPLANT, V10, P42, DOI 10.1111/j.1399-3046.2005.00395.x
  2. Arnon R, 2011, PEDIATR TRANSPLANT, V15, P400, DOI 10.1111/j.1399-3046.2011.01497.x
  3. Beaunoyer M, 2007, PEDIATR TRANSPLANT, V11, P655, DOI 10.1111/j.1399-3046.2007.00751.x
  4. Buyukpamukcu M, 2006, PEDIATR TRANSPLANT, V10, P517, DOI 10.1111/j.1399-3046.2006.00511.x
  5. Crone J, 2003, ACTA PAEDIATR, V92, P625
  6. de Laet C, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-8
  7. EDMONDSON HA, 1954, CANCER, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
  8. El-Karaksy H, 2011, WORLD J PEDIATR, V7, P224, DOI 10.1007/s12519-011-0287-3
  9. Forget S, 1999, PEDIATR RADIOL, V29, P104, DOI 10.1007/s002470050551
  10. Gambarin-Gelwan M, 2000, AM J GASTROENTEROL, V95, P1535
  11. Hadzic N, 2011, CLIN LIVER DIS, V15, P443, DOI 10.1016/j.cld.2011.03.011
  12. Holme E, 1998, J INHERIT METAB DIS, V21, P507, DOI 10.1023/A:1005410820201
  13. Holme E, 2000, Clin Liver Dis, V4, P805, DOI 10.1016/S1089-3261(05)70142-2
  14. Jacobs SMM, 2006, PEDIATR RES, V59, P365, DOI 10.1203/01.pdr.0000198810.57642.b4
  15. Jorquera R, 2001, HUM MOL GENET, V10, P1741, DOI 10.1093/hmg/10.17.1741
  16. Kalicinski P, 2009, PEDIATR TRANSPLANT, V13, P657, DOI 10.1111/j.1399-3046.2009.01210.x
  17. Katzenstein BH, 2013, J CLIN ONCOL, V20, P2789
  18. Kim H, 2000, LIVER, V20, P173, DOI 10.1034/j.1600-0676.2000.020002173.x
  19. Koelink CJL, 2006, MOL GENET METAB, V89, P310, DOI 10.1016/j.ymgme.2006.07.009
  20. Lee JM, 2012, SEMIN ONCOL, V39, P399, DOI 10.1053/j.seminoncol.2012.05.010
  21. Masurel-Paulet A, 2008, J INHERIT METAB DIS, V31, P81, DOI 10.1007/s10545-008-0793-1
  22. Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
  23. McDiarmid SV, 2002, TRANSPLANTATION, V74, P173, DOI 10.1097/00007890-200207270-00006
  24. McKiernan PJ, 2006, DRUGS, V66, P743, DOI 10.2165/00003495-200666060-00002
  25. Mohan N, 1999, EUR J PEDIATR, V158, pS49, DOI 10.1007/PL00014321
  26. Moore SW, 2004, CANCER, V101, P642, DOI 10.1002/cncr.20398
  27. Morioka D, 2005, AM J TRANSPLANT, V5, P2754, DOI 10.1111/j.1600-6143.2005.01084.x
  28. Otte JB, 2008, PEDIATR TRANSPLANT, V12, P1, DOI 10.1111/j.1399-3046.2007.00852.x
  29. Ozcay F, 2006, CLIN TRANSPLANT, V20, P776, DOI 10.1111/j.1399-0012.2006.00571.x
  30. Pham TH, 2007, J PEDIATR SURG, V42, P834, DOI 10.1016/j.jpedsurg.2006.12.065
  31. Reyes JD, 2000, J PEDIATR, V136, P795, DOI 10.1067/mpd.2000.106223
  32. RUSSO P, 1990, AM J HUM GENET, V47, P317
  33. Russo PA, 2001, PEDIATR DEVEL PATHOL, V4, P212, DOI 10.1007/s100240010146
  34. Shneider BL, 2002, PEDIATR TRANSPLANT, V6, P25, DOI 10.1034/j.1399-3046.2002.1p057.x
  35. Spronsen FJ, 2005, J PEDIAT GASTROENTER, V40, P90
  36. Superina R, 1996, J PEDIATR SURG, V31, P835, DOI 10.1016/S0022-3468(96)90147-5
  37. TORTAJADA JFI, 2008, AN PEDIATR, V68, P377
  38. Weeda VB, 2013, EUR J CANCER, V49, P2698, DOI 10.1016/j.ejca.2013.04.012

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03